Welcome to our dedicated page for Waldencast plc SEC filings (Ticker: WALD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waldencast plc has more than pretty packaging. Its SEC reports unpack how Obagi Skincare and Milk Makeup each contribute to revenue, margins, and goodwill after recent acquisitions. If you have ever searched “Waldencast SEC filings explained simply,” you already know the challenge—hundreds of pages of brand-level data, intangible-asset roll-forwards, and stock-based compensation tables.
Our platform delivers the details investors ask for most:
- 10-K annual report – brand segment sales, impairment tests, and cash-flow drivers, now in an AI-generated brief labelled “Waldencast annual report 10-K simplified.”
- 10-Q quarterly earnings report – real-time alerts so you never miss a “Waldencast quarterly earnings report 10-Q filing.”
- 8-K material events – product launches, acquisition milestones, and financing updates, all under “Waldencast 8-K material events explained.”
- Form 4 insider transactions – see “Waldencast Form 4 insider transactions real-time” and track executive stock moves before and after key launches.
- Proxy statement – concise AI notes on “Waldencast proxy statement executive compensation.”
Behind every filing, Stock Titan’s AI translates accounting jargon into clear insights. Compare Obagi vs. Milk Makeup growth, monitor “Waldencast earnings report filing analysis,” or set alerts for “Waldencast executive stock transactions Form 4.” Real-time EDGAR feeds combined with machine summarization mean you can focus on decisions, not document hunts. Start understanding Waldencast SEC documents with AI—because beauty sector complexity shouldn’t hide in footnotes.
Waldencast plc is registering up to 9,819,000 Class A ordinary shares for resale by existing holders, not for a new capital raise. These shares are contingent consideration from the Novaestiq acquisition and relate to exclusive U.S. commercialization rights for saypha-branded cosmetic filler products. The package includes 3,273,000 shares already earned upon FDA approval of Obagi saypha MagIQ injectable hyaluronic acid gel and up to 6,546,000 additional shares tied to future sales milestones.
The sellers, primarily Croma-Pharma GmbH and NVQ Investors Holding, LLC, may sell their shares over time under this shelf prospectus, while Waldencast receives no proceeds from these resales but covers registration expenses. The Novaestiq deal also includes $3.0 million in cash and a 5.0% share of net sales of Phase 1 products above $120.0 million, plus lock-up schedules that stagger when milestone shares can be sold, which may influence future trading volumes in Waldencast stock.
Waldencast plc has furnished a Form 6-K announcing that it has released its Q2 2025 financial results and a Q3 2025 trading update. The company reports on business and financial performance for the three and six months ended June 30, 2025, and provides a trading update for the three months ended September 30, 2025, via a press release attached as Exhibit 99.1. The Form 6-K states that this information is being furnished rather than filed and will only be incorporated by reference into other filings if specifically referenced.
Waldencast plc filed a Form 6-K to provide its unaudited interim consolidated financial statements for the six months ended June 30, 2025. These H1 2025 interim financials are furnished as Exhibit 99.1.
The filing also lists several material agreements as exhibits, including a Credit Agreement dated November 14, 2025 involving Milk Makeup LLC, Obagi Cosmeceuticals LLC, Waldencast Partners plc as parent guarantor, various lenders and LSSF II Offshore Investments, LP as administrative agent. In addition, it includes a Trademark Transfer Agreement and a Trademark Coexistence Agreement, both dated November 13, 2025, between Rohto Pharmaceutical Co., Ltd. and Obagi Cosmeceuticals LLC.
The report and its exhibits are incorporated by reference into Waldencast’s existing registration statements on Form S-8 and Form F-3, meaning these interim financials and agreements now form part of those shelf and incentive plan disclosures.
Waldencast plc reported updates via a Form 6-K, noting the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. The company characterized these steps as strengthening its balance sheet.
A press release dated November 14, 2025 is attached as Exhibit 99.1 for further details. The information in this report, including the exhibit, is designated as not “filed” under Section 18 of the Exchange Act.
FAQ
What is the current stock price of Waldencast plc (WALD)?
What is the market cap of Waldencast plc (WALD)?
